SAN FRANCISCO, Jan 13 (Reuters) - AstraZeneca has agreed to buy Boston-based Modella AI, the companies said on Tuesday, as the drug industry increases its use of artificial intelligence to accelerate the discovery of new drugs.
The companies did not disclose financial terms. In a press release, Modella AI said its "foundation models" and AI agents would be integrated into oncology research and development to support clinical development and biomarker discovery.
"Oncology drug development is becoming more complex, more data-rich and more time-sensitive," said Gabi Raia, Modella AI's chief commercial officer, adding that joining AstraZeneca would allow it to deploy its tools in global trials and clinical settings.
AstraZeneca said that this was the first acquisition of an AI firm by a big pharmaceutical company.
In an interview at the JP Morgan Healthcare Conference, AstraZeneca Chief Financial Officer Aradhana Sarin said the acquisition would "supercharge" the company's quantitative pathology and biomarker discovery efforts by bringing more data and AI capabilities in-house.
The deal was one of a number of pacts between major drug firms and AI companies that were unveiled at the healthcare conference, including a $1 billion collaboration between Nvidia and Eli Lilly. They plan to build a new research lab using Nvidia's latest-generation AI chips.
Modella will accelerate AstraZeneca’s efforts to make pathology more quantitative - using computers to analyze biopsies for relevant proteins and correlate them with clinical data - so AstraZeneca can develop “highly targeted biomarkers and then highly targeted therapeutics,” Sarin said.
The deal is an expansion of a multi-year collaboration that the companies unveiled in July.
Sarin said that partnership served as a "test drive," adding that AstraZeneca ultimately wanted Modella's data, foundation models and AI talent in-house.
She said AI tools could be used to more rapidly select patients for drug trials, which could increase the odds of clinical success and cut related costs.
(Reporting by Maggie Fick; Editing by Thomas Derpinghaus)
LATEST POSTS
- 1
These 45 exoplanets may be the best places to search for alien life - 2UPM Adhesive Materials plans new facility near New Delhi, India
- 3At least 7 dead as Israel renews attacks on Beirut and across Lebanon
- 4French Senate debates social media ban for under-15s
- 5Jupiter and the moon take a sunset stroll on March 26. Here's how to see it
- What exactly is the Upside Down in 'Stranger Things'? The wormhole revelation, explained.
- Iran war drives global fertilizer prices up, raising food cost fears
- Minute Maid’s frozen juice concentrate is ending after 80 years — and so is a certain kind of kitchen ritual
- Merck sees over $5 billion opportunity in Cidara's experimental flu drug
- South African army arrive in crime hotspots to help tackle gangs
- Hamas demanded displaced Gazans pay rent on beach tents amid torrential downpour, IDF reveals
- Signature Scents: A Manual for Outstanding Fragrances
- Catch the moon dancing with bright star Regulus tonight
- Ukraine proved this drone-killer works. Now, the West is giving it a shot.
